Lilly's valuation seems reasonable given its growth prospects. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY ...

Camurus AB reported its second-quarter earnings for 2025, revealing a robust financial performance with earnings per share (EPS) of 4.08, significantly surpassing the forecasted 3.27. The company’s ...

Camurus AB reported its second-quarter earnings for 2025, revealing a robust financial performance with earnings per share (EPS) of 4.08, significantly surpassing the forecasted 3.27. The company ...

Camurus AB (STO:CAMX) presented its second quarter 2025 results on July 17, revealing record financial performance and significant progress across its product portfolio.

"Successful second quarter for Camurus" Summary second quarter 2025 April - June Total revenues grew 52% (65% at CER1) to SEK 676 (445) million Sales of Buvidal® increased 17% (26% at CER1) to SEK ...

Camurus, an international, science-led biopharmaceutical company, announced that the European Commission (EC) has granted Oczyesa, octreotide subcutaneous depot, marketing authorization for the ...

Camurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and ...

Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX.

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compoundsCamurus eligible to receive up to $870 million in ...

Camurus (NASDAQ STO: CAMX) and Eli Lilly and Company ("Lilly") have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, ...

Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty "We are pleased to enter into this collaboration with Lilly to ...